New Treatments in Renal Cancer: The AhR Ligands

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Kidney cancer develops resistance to antiangiogenic drugs like sunitinib, often through enhanced cell migration via c-Met signaling.
• The Aryl hydrocarbon receptor (AhR) is a potential molecular target for cancer therapy.
• Aminoflavone (AFP 464) and Phortress (5F 203) are clinically tested AhR ligands with activity against renal cancer.

Purpose of the Study:

• To investigate the effects of AFP 464 and 5F 203 on renal cancer cell cycle progression, apoptosis, and migration.
• To determine the impact of these compounds on c-Met signaling pathways involved in cell migration.
• To explore the potential of nano-delivery systems for benzothiazole-based renal cancer treatments.

Main Methods:

• Treatment of renal cancer cell lines (TK-10, Caki-1, SN12C) with AFP 464 and 5F 203.
• Assessment of cell cycle progression and apoptosis using standard assays.
• Evaluation of cell migration inhibition and effects on c-Met signaling cascade.
• In vitro testing of apoferritin-encapsulated benzothiazoles (5F 203, GW610) against TK-10 cells.

Main Results:

• Both AFP 464 and 5F 203 induced cell cycle arrest and apoptosis in renal cancer cells.
• 5F 203 significantly inhibited cell migration in TK-10, Caki-1, and SN12C cell lines.
• 5F 203 potently suppressed the c-Met signaling cascade in TK-10 cells.
• Apoferritin-encapsulated benzothiazoles demonstrated enhanced in vitro antitumor effects at lower concentrations compared to naked agents.

Conclusions:

• The benzothiazole 5F 203 exhibits potent anti-migratory effects against kidney cancer cells by inhibiting c-Met signaling.
• AFP 464 and 5F 203 show potential as therapeutic agents for renal cancer, with 5F 203 demonstrating superior anti-migratory activity.
• Nano-delivery vehicles offer a promising strategy for improving the efficacy of benzothiazole-based renal cancer therapies.